Catalyst Pharmaceuticals(CPRX)
Focus: Catalyst is a publicly traded specialty pharmaceutical company focused on small molecules for rare neurological and neuromuscular disorders. The company generates ~$398M in annual revenue driven primarily by FIRDAPSE (amifampridine phosphate) for Lambert-Eaton Myasthenic Syndrome and related conditions.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
5
Should You Work at Catalyst Pharmaceuticals?
AI assessmentCatalyst offers clinical depth and financial stability but carries high single-product concentration risk and a near-term patent cliff that may trigger restructuring before pipeline catalysts mature.
Why Work Here
- Strong revenue growth trajectory (+86% YoY to $398M FY2025) with profitability ($71M net income), providing stability and resources for development.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
2 imminent
FYCOMPA
Hiring
Stable
Revenue
$398M
FY2025
Key Products
$146M Part DStable
Peak
Help build intelligence for Catalyst Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.